BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Danny Kim who wrote (6)	6/21/1997 9:59:00 PM
From: geewiz	of 534

Time to wake up this thread!!!!!! Danny and all, I admit to being very long on BJCT. I first read about it in the Oregonian Newspaper in December of 1994 when the original chairman, Willcox was being forced out by shareholders. I've added lots to my original holding. Every time I visit the company I am reassured that it is becoming increasingly focused and determined to succeed as the injection company of the next decade. On a preceeding post Bluefiish stated that the concern over the HIV crisis was BJCT's edge. There is some truth to that; initial research funds came from the CDC. That's not such a bad start! Larger concerns regarding biomedical waste and nurse liability have superseded this initial interest. Note that in the most recent newsrelease regarding the flue injections at WallMart, it was the Visiting Nurses that chose the Bioject vector due to liability limitations. So what does the investor get for 62 cents? There is 4 million cash on the books and we've got 19 million shares outstanding; so I figure 21 cents a share is cash. The balance represents five years of perfecting three injection vectors: the original clinical model 2000; the self-injector developed for Schering; and a third model for multiple injections being developed for the military. We have FDA approval on both the self-injector and the model 2000. In April I asked how many model 2000's were in circulation; about 2300 give or take. Jim O'Shea (CEO) mentioned several years ago that he saw the opportunity not in selling the Biojector, but in selling the CO2 charge cartrige and disposable syringes. In fact a big chunk of our $900,000 R&D expenses from last year were used to perfect the disposible syringe for the self-injector. This is what really makes the BJCT opportunity so compelling; we will be selling the Biojector at cost and selling the supplies at a nice margin. It is difficult to put a value on this because we have had such a struggle getting to market. But look at what Abbott paid for Carpuject! pcquote.newsalert.com Abbott bought an old technology so they could acheive the same packaging opportunity that we will have when we find a major drug company to committ to our technology. I've more thoughts on BJCT if anyone is interested; there is also a list of studies available from the company that I found on the web. In closing I'd like to comment about hyping a stock. I am long BJCT for reasons I've stated above, plus others. I share it here so others can do their own research. It is just not possible for me to really influence the price of the stock by what is shared here. There are 19 million shares and I doubt 50 SI'er hit this site. There was a single trade of 80,000 shares traded last Friday and the price did not budge! If I thought a positive hype would move the stock price I would have tried it long ago. best Art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next